Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
NK911 is a novel supramolecular nanocarrier designed for the enhanced delivery of doxorubicin (DXR) and is one of the successful polymer micelle systems to exhibit an efficient accumulation in solid tumours in mice. The purpose of this study was to define the maximum-tolerated dose (MTD) and dose-limiting toxicities (DLTs) of NK911 and to evaluate its pharmacokinetic profile in man. NK911 was given intravenously to patients with solid tumours every 3 weeks using an infusion pump at a rate of 10 mg DXR equivalent min(-1). The starting dose was 6 mg DXR equivalent m(-2), and the dose was escalated according to the accelerated titration method. A total of 23 patients participated in this study. Neutropenia was the predominant haematological toxicity, and grade 3 or 4 neutropenia was observed at doses of 50 and 67 mg m(-2). Common nonhaematological toxicities were mild alopecia, stomatitis, and anorexia. In the dose identification part of the study, DLTs were observed at a dose of 67 mg m(-2) (grade 4 neutropenia lasting more than 5 days). Thus, this dosage level was determined to be the MTD. Infusion-related reactions were not observed in any cases. The C(5 min) and area under the concentration curve parameters of NK911 exhibited dose-dependent characteristics. Among the 23 patients, a partial response was obtained in one patient with metastatic pancreatic cancer. NK911 was well tolerated and produced only moderate nausea and vomiting at myelosuppressive dosages. The recommended phase II dose was determined to be 50 mg m(-2) every 3 weeks.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This same concept was used by Kataoka and colleagues in a series of works leading to development of polymeric micelle NK911, which was evaluated clinically [146, 147].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [146]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Self-citationTumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565 · cited 1×
“These characteristics, which are unique to solid tumours, constitute the basis of the enhanced permeability and retention (EPR) effect (Matsumura and Maeda, 1986; Maeda et al, 2000).”
BackgroundSelf-citationWHO Handbook for Reporting Results of Cancer Treatment
Palmer, M. K. (1982) · British Journal of Cancer · doi:10.1038/bjc.1982.83 · Cited by 2,198
Gabizón, A., Catane, R., Uziely, B., Kaufman, B., Safra, T., Cohen, R., Martin, F., Huang, A., & Barenholz, Y. (1994) · PubMed · Cited by 1,382
Gordon, A. N., Fleagle, J. T., Guthrie, D., Parkin, D. E., Gore, M. E., & Lacave, A. J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.14.3312 · Cited by 1,211 · cited 2×
“No infusionrelated reactions, which are sometimes seen in cases of liposomal drug administration (Uziely et al, 1995; Muggia et al, 1996; Stewart et al, 1998; Gordon et al, 2001), occurred in this trial.”
BackgroundMuggia, F. M., Hainsworth, J. D., Jeffers, S., Miller, P., Groshen, S., Tan, M., Roman, L., Uziely, B., Muderspach, L., Garcia, A., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.987 · Cited by 647 · cited 2×
“No infusionrelated reactions, which are sometimes seen in cases of liposomal drug administration (Uziely et al, 1995; Muggia et al, 1996; Stewart et al, 1998; Gordon et al, 2001), occurred in this trial.”
BackgroundAccelerated Titration Designs for Phase I Clinical Trials in Oncology
Simon, R., Rubinstein, L., Arbuck, S. G., Christian, M. C., Freidlin, B., & Collins, J. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.15.1138 · Cited by 639 · cited 2×
“Dose escalation was performed according to the previously described accelerated titration method (Simon et al, 1997).”
MethodDevelopment of the polymer micelle carrier system for doxorubicin
Nakanishi, T., Fukushima, S., Okamoto, K., Suzuki, M., Matsumura, Y., Yokoyama, M., Okano, T., Sakurai, Y., & Kataoka, K. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00341-8 · Cited by 570 · cited 7×
“The hydrophobic inner core enables NK911 to entrap a sufficient amount of DXR. NK911 has a diameter of about 40 nm (Nakanishi et al, 2001).”
BackgroundMethodSelf-citationUziely, B., Jeffers, S., Isacson, R., Kutsch, K., Wei-Tsao, D., Yehoshua, Z., Libson, E., Muggia, F. M., & Gabizon, A. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.7.1777 · Cited by 477 · cited 1×
“No infusionrelated reactions, which are sometimes seen in cases of liposomal drug administration (Uziely et al, 1995; Muggia et al, 1996; Stewart et al, 1998; Gordon et al, 2001), occurred in this trial.”
Background(1991) · PubMed · Cited by 418
Cited by
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Biodegradable polymers as biomaterials
Nair, L. S., & Laurencin, C. T. (2007) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2007.05.017 · Cited by 4,416
Nanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233
Factors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699
Kamaly, N., Yameen, B., Wu, J., & Farokhzad, O. C. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00346 · Cited by 3,070
Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size
Cabral, H., Matsumoto, Y., Mizuno, K., Chen, Q., Murakami, M., Kimura, M., Terada, Y., Kano, M. R., Miyazono, K., Uesaka, M., et al. (2011) · Nature Nanotechnology · doi:10.1038/nnano.2011.166 · Cited by 2,429
Tumor delivery of macromolecular drugs based on the EPR effect
Torchilin, V. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.03.011 · Cited by 2,032
Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications
Wicki, A., Witzigmann, D., Balasubramanian, V., & Huwyler, J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.030 · Cited by 1,901
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy
Pérez-Herrero, E., & Fernández-Medarde, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.03.018 · Cited by 1,875
Ulbrich, K., Holá, K., Šubr, V., Bakandritsos, A., Tuček, J., & Zbořil, R. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00589 · Cited by 1,730
Targeted polymeric therapeutic nanoparticles: design, development and clinical translation
Kamaly, N., Xiao, Z., Valencia, P. M., Radovic-Moreno, A. F., & Farokhzad, O. C. (2012) · Chemical Society Reviews · doi:10.1039/c2cs15344k · Cited by 1,730
Nanoparticle Delivery of Cancer Drugs
Wang, A. Z., Langer, R., & Farokhzad, O. C. (2012) · Annual Review of Medicine · doi:10.1146/annurev-med-040210-162544 · Cited by 1,561
Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress
Lammers, T., Kiessling, F., Hennink, W. E., & Storm, G. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.063 · Cited by 1,324
Multifunctional polymeric micelles as cancer-targeted, MRI-ultrasensitive drug delivery systems
Nasongkla, N., Bey, E., Ren, J., Ai, H., Khemtong, C., Guthi, J. S., Chin, S.-F., Sherry, A. D., Boothman, D. A., & Gao, J. (2006) · Nano Letters · doi:10.1021/nl061412u · Cited by 1,238
Polymeric Nanoparticles for Drug Delivery
Beach, M. A., Nayanathara, U., Gao, Y., Zhang, C., Xiong, Y., Wang, Y., & Such, G. K. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00705 · Cited by 1,155
Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect
Maeda, H., Bharate, G. Y., & Daruwalla, J. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.11.010 · Cited by 1,168
Nishiyama, N., & Kataoka, K. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.05.006 · Cited by 1,052
Physical stimuli-responsive polymeric micelles for anti-cancer drug delivery
Rapoport, N. (2007) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2007.05.009 · Cited by 1,002
Owen, S. C., Chan, D. P. Y., & Shoichet, M. S. (2012) · Nano Today · doi:10.1016/j.nantod.2012.01.002 · Cited by 911
Polymer–drug conjugate therapeutics: advances, insights and prospects
Ekladious, I., Colson, Y. L., & Grinstaff, M. W. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0005-0 · Cited by 855
Progress of drug-loaded polymeric micelles into clinical studies
Cabral, H., & Kataoka, K. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.042 · Cited by 837
Clinical Translation of Nanomedicine
Min, Y., Caster, J. M., Eblan, M. J., & Wang, A. Z. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00116 · Cited by 772
Fang, J., Islam, W., & Maeda, H. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.005 · Cited by 757
Role of nanotechnology in targeted drug delivery and imaging: a concise review
Koo, O. M., Rubinstein, I., & Onyuksel, H. (2005) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2005.06.004 · Cited by 718
“poly(amino acids) requires validation Doxorubicin (NK911) [128,129]”
BackgroundHwang, D., Ramsey, J. D., & Kabanov, A. V. (2020) · Advanced drug delivery reviews · doi:10.1016/j.addr.2020.09.009 · Cited by 699
Application of Nanotechnology in Cancer Therapy and Imaging
Wang, X., Yang, L., Chen, Z., & Shin, D. M. (2008) · CA: A Cancer Journal for Clinicians · doi:10.3322/ca.2007.0003 · Cited by 700
Nanonization strategies for poorly water-soluble drugs
Chen, H., Khemtong, C., Yang, X., Chang, X., & Gao, J. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2010.02.009 · Cited by 642
Passive and Active Drug Targeting: Drug Delivery to Tumors as an Example
Torchilin, V. P. (2010) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-00477-3_1 · Cited by 573
Polymeric micelles and alternative nanonized delivery vehicles for poorly soluble drugs
Lu, Y., & Park, K. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.08.042 · Cited by 572
“NK105 NK105 is a formulation consisting of paclitaxel physically incorporated into polymeric micelles self-assembled from PEG-poly(aspartic acid) (PEG-P(Asp)) modified with 4-phenyl-1butanol to increase the hydrophobicity (Matsumura et al., 2004).”
Polymeric micelles drug delivery system in oncology
Gong, J., Chen, M., Zheng, Y., Wang, S., & Wang, Y. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.12.012 · Cited by 570
Deng, C., Jiang, Y., Cheng, R., Meng, F., & Zhong, Z. (2012) · Nano Today · doi:10.1016/j.nantod.2012.08.005 · Cited by 562
Functionalized micellar systems for cancer targeted drug delivery
Sutton, D., Nasongkla, N., Blanco, E., & Gao, J. (2007) · Pharmaceutical Research · doi:10.1007/s11095-006-9223-y · Cited by 557
Kim, S., Shi, Y., Kim, J. Y., Park, K., & Cheng, J.-X. (2010) · Expert Opinion on Drug Delivery · doi:10.1517/17425240903380446 · Cited by 549
“In spite of seductive advantages, only four micelle systems have been clinically examined [10-16].”
BackgroundLigand-Directed Active Tumor-Targeting Polymeric Nanoparticles for Cancer Chemotherapy
Zhong, Y., Meng, F., Deng, C., & Zhong, Z. (2014) · Biomacromolecules · doi:10.1021/bm5003009 · Cited by 541
Yuan, Y., Mao, C., Du, X., Du, J., Wang, F., & Wang, J. (2012) · Advanced Materials · doi:10.1002/adma.201202296 · Cited by 529
Talelli, M., Barz, M., Rijcken, C. J. F., Kiessling, F., Hennink, W. E., & Lammers, T. (2015) · Nano Today · doi:10.1016/j.nantod.2015.01.005 · Cited by 506
Targeted therapy using nanotechnology: focus on cancer
Sechi, M., Sanna, V., & Pala, N. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s36654 · Cited by 493
“69 Moreover, Opaxio™ (formerly Xyotax™), also a passively targeted paclitaxel/poly(L-glutamic acid) nanoconstruct, is proving effective in ovarian tumors, 70,71 and CRLX101 (formerly IT-101), a camptothecin-cyclodextrin polymer conjugate, is showing enhanced pharmacokinetic efficacy in both…”
Rijcken, C. J. F., Soga, O., Hennink, W. E., & Nostrum, C. F. V. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.03.023 · Cited by 487
Recent advances in polymeric micelles for anti-cancer drug delivery
Biswas, S., Kumari, P., Lakhani, P. M., & Ghosh, B. (2016) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2015.12.031 · Cited by 471
Multifunctional polymeric micelles for delivery of drugs and siRNA
Jhaveri, A. M., & Torchilin, V. P. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00077 · Cited by 466
“We can thus engineer micelles to have two or more different modifications that enable them to simultaneously or sequentially perform important therapeutic and diagnostic functions (Torchilin, 2006).”
BackgroundStimuli‐Responsive Polymersomes as Nanocarriers for Drug and Gene Delivery
Onaca, O., Enea, R., Hughes, D. W., & Meier, W. (2009) · Macromolecular Bioscience · doi:10.1002/mabi.200800248 · Cited by 465
Gene therapy and DNA delivery systems
Ibraheem, D., Elaissari, A., & Fessi, H. (2014) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.11.041 · Cited by 454
Polymeric micelles for drug delivery
Aliabadi, H. M., & Lavasanifar, A. (2006) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.3.1.139 · Cited by 446
“The results of Phase I clinical trials and human pharmacokinetic studies on NK-911 showed a similar spectrum in the side effects and recommended dose for NK-911 and free DOX [99].”
BackgroundSun, H., Guo, B., Cheng, R., Meng, F., Liu, H., & Zhong, Z. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.07.051 · Cited by 438
New Generation of Multifunctional Nanoparticles for Cancer Imaging and Therapy
Park, K., Lee, S., Kang, E., Kim, K., Choi, K., & Kwon, I. C. (2009) · Advanced Functional Materials · doi:10.1002/adfm.200801655 · Cited by 432
Uchino, H., Matsumura, Y., Negishi, T., Koizumi, F., Hayashi, T., Honda, T., Nishiyama, N., Kataoka, K., Naito, S., & Kakizoe, T. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602772 · Cited by 430
“The Phase I clinical trial of adriamycin-incorporating polymeric micelles has been completed (Matsumura et al, 2004).”
BackgroundSelf-citationWei, Z., Hao, J., Yuan, S., Li, Y., Juan, W., Sha, X., & Fang, X. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.04.030 · Cited by 427
Receptor-targeted nanocarriers for therapeutic delivery to cancer
Yu, B., Tai, H. C., Xue, W., Lee, L. J., & Lee, R. J. (2010) · Molecular Membrane Biology · doi:10.3109/09687688.2010.521200 · Cited by 423
“SP1049C, a micelle formulation of doxorubicin comprising pluronics, and NK911, another micelle formulation of doxorubicin comprising polyethylene glycol-poly (aspartic acid) block copolymer have been studied in clinical trials (Danson et al. 2004, Matsumura et al. 2004).”
Aghebati‐Maleki, A., Dolati, S., Ahmadi, M., Baghbanzhadeh, A., Asadi, M., Fotouhi, A., Yousefi, M., & Aghebati‐Maleki, L. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29126 · Cited by 417
“Drug molecules are attached to dendrimers in complex or capsule forms (Madaan, Kumar, Poonia, Lather, & Pandita, 2014; Matsumura et al., 2004).”
BackgroundPolymeric mixed micelles as nanomedicines: Achievements and perspectives
Cagel, M., Tesan, F. C., Bernabeu, E., Salgueiro, M. J., Zubillaga, M. B., Moretton, M. A., & Chiappetta, D. A. (2017) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2016.12.019 · Cited by 417
Choi, Y. H., & Han, H.-K. (2018) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-017-0370-4 · Cited by 406
“Albumin nanoparticles of paclitaxel improves targeting variability by increasing delivery to cancer cells when intravenously administered (Asthana et al. 2005; Barenholz 2012; Chaturvedi et al. 2013; Fanciullino et al. 2013; Feldman et al. 2012; Fetterly and Straubinger 2003; Hanafy et al. 2007; Hrkach et al. 2012; Ji…”
BackgroundInfluentialRecent progress in biomedical applications of pluronic (PF127): Pharmaceutical perspectives
Akash, M. S. H., & Rehman, K. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.04.032 · Cited by 394
Nanodrugs: pharmacokinetics and safety
Onoue, S., Yamada, S., & Chan, K. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s38378 · Cited by 382
Caster, J. M., Patel, A. N., Zhang, T., & Wang, A. (2017) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1416 · Cited by 380
Nanoparticle Technologies for Cancer Therapy
Alexis, F., Pridgen, E. M., Langer, R., & Farokhzad, O. C. (2010) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-00477-3_2 · Cited by 364
“2007), and NK911 (Matsumura et al. 2004; Tsukioka et al. 2002).”
BackgroundCheetham, A. G., Chakroun, R. W., Ma, W., & Cui, H. (2017) · Chem. Soc. Rev. · doi:10.1039/c7cs00521k · Cited by 367
Zhang, W., Shi, Y., Chen, Y., Ye, J., Sha, X., & Fang, X. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2010.12.039 · Cited by 368
Polymeric micelles: nanocarriers for cancer-targeted drug delivery
Zhang, Y., Huang, Y., & Li, S. (2014) · AAPS PharmSciTech · doi:10.1208/s12249-014-0113-z · Cited by 367
“NK105 (16), pluronic polymer-bound doxorubicin (SP1049C) (17) and NK911, a micelle-encapsulated doxorubicin (18).”
Polymeric nanostructured materials for biomedical applications
Tang, Z., He, C., Tian, H., Ding, J., Hsiao, B. S., Chu, B., & Chen, X. (2016) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2016.05.005 · Cited by 363
Doxorubicin: nanotechnological overviews from bench to bedside
Cagel, M., Grotz, E., Bernabeu, E., Moretton, M. A., & Chiappetta, D. A. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2016.11.005 · Cited by 362
Hypoxia-responsive polymeric nanoparticles for tumor-targeted drug delivery
Thambi, T., Deepagan, V. G., Yoon, H. Y., Han, H. S., Kim, S.-H., Son, S., Jo, D.-G., Ahn, C.-H., Suh, Y. D., Kim, K., et al. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2013.11.022 · Cited by 359
Manganese ferrite nanoparticle micellar nanocomposites as MRI contrast agent for liver imaging
Lu, J., Ma, S., Sun, J., Xia, C., Liu, C., Wang, Z., Zhao, X., Gao, F., Gong, Q., Song, B., et al. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.02.001 · Cited by 359
“, have led to their use in hydrophobic small molecule anti-cancer drug encapsulation [22,24–26], and some of the formulations are already in clinical trials [27,28].”
BackgroundProdrug-based nanoparticulate drug delivery strategies for cancer therapy
Luo, C., Sun, J., Sun, B., & He, Z. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.09.008 · Cited by 352
Lee, H., Fonge, H., Hoang, B., Reilly, R. M., & Allen, C. (2010) · Molecular Pharmaceutics · doi:10.1021/mp100038h · Cited by 349
Kim, K., Kim, J. H., Park, H., Kim, Y.-S., Park, K., Nam, H., Lee, S., Park, J. H., Park, R.-W., & Kim, I.-S. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.04.004 · Cited by 347
Nanotechnology in Cancer Drug Delivery and Selective Targeting
Sutradhar, K. B., & Amin, M. L. (2014) · ISRN Nanotechnology · doi:10.1155/2014/939378 · Cited by 241
Rasines Mazo, A., Allison-Logan, S., Karimi, F., Chan, N. J.-A., Qiu, W., Duan, W., O’Brien-Simpson, N. M., & Qiao, G. G. (2020) · Chemical Society Reviews · doi:10.1039/c9cs00738e · Cited by 329
Fernandez-Fernandez, A., Manchanda, R., & McGoron, A. J. (2011) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-011-9383-z · Cited by 330
Multifunctional Micellar Nanomedicine for Cancer Therapy
Blanco, E., Kessinger, C. W., Sumer, B. D., & Gao, J. (2009) · Experimental Biology and Medicine · doi:10.3181/0808-mr-250 · Cited by 332
“8 hrs) and reduced the clearance of the drug (26).”
Mikhail, A. S., & Allen, C. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.04.010 · Cited by 328
Clinical toxicities of nanocarrier systems.
Vega-Villa, K. R., Takemoto, J. K., Yáñez, J. A., Remsberg, C. M., Forrest, M. L., & Davies, N. M. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.11.007 · Cited by 325
Shafei, A., El-Bakly, W., Sobhy, A., Wagdy, O., Reda, A., Aboelenin, O., Marzouk, A., El Habak, K., Mostafa, R., Ali, M. A., et al. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.09.059 · Cited by 318
Anticancer Polymeric Nanomedicines
Tong, R., & Cheng, J. (2007) · Polymer Reviews · doi:10.1080/15583720701455079 · Cited by 310
“In a Phase I study, the toxicity of NK911 resembled that of free DOXO, and the dose-limiting toxicity was neutropenia.(158) NK911 is currently being evaluated in a phase II clinical trial.”
BackgroundNanotechnology: A Promising Approach for Delivery of Neuroprotective Drugs
Naqvi, S., Panghal, A., & Flora, S. J. S. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00494 · Cited by 305
Nanomedicine applied to translational oncology: A future perspective on cancer treatment
Bregoli, L., Movia, D., Gavigan-Imedio, J. D., Lysaght, J., Reynolds, J., & Prina-Mello, A. (2016) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2015.08.006 · Cited by 296
“NK911 completed a phase-1 clinical trial phase in 2004 (124).”
BackgroundHamaguchi, T., Kato, K., Yasui, H., Morizane, C., Ikeda, M., Ueno, H., Muro, K., Yamada, Y., Okusaka, T., Shirao, K., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603855 · Cited by 290
“NK105 solution was infused using an electric pump at a speed of 250 ml h 1.”
MethodSelf-citationMicelles structure development as a strategy to improve smart cancer therapy
Hanafy, N., El-Kemary, M., & Leporatti, S. (2018) · Cancers · doi:10.3390/cancers10070238 · Cited by 287
“The hydrophobic core of micelles designed from lipid conjugated PEG can be occupied by several insoluble drugs, such as paclitaxel, tamoxifen, porphyrin [91], camptothecin [92], and vitamin K3 [93].”
BackgroundStealth nanoparticles in oncology: Facing the PEG dilemma
Zalba, S., ten Hagen, T. L. M., Burgui, C., & Garrido, M. J. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.09.002 · Cited by 278
Polyphenol nanoformulations for cancer therapy: experimental evidence and clinical perspective
Davatgaran-Taghipour, Y., Masoomzadeh, S., Farzaei, M. H., Bahramsoltani, R., Karimi-Soureh, Z., Rahimi, R., & Abdollahi, M. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s131973 · Cited by 281
Nanomedicine in the diagnosis and therapy of neurodegenerative disorders
Kabanov, A. V., & Gendelman, H. E. (2007) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2007.05.014 · Cited by 277
“[146] Matsumura Y, et al.”
BackgroundNanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research
Egusquiaguirre, S. P., Igartua, M., Hernández, R. M., & Pedraz, J. L. (2012) · Clinical and Translational Oncology · doi:10.1007/s12094-012-0766-6 · Cited by 268
Nishiyama, N., Morimoto, Y., Jang, W.-D., & Kataoka, K. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.01.004 · Cited by 266
Polymeric micelles in oral chemotherapy
Bromberg, L. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.01.018 · Cited by 264
Improving Drug Potency and Efficacy by Nanocarrier-Mediated Subcellular Targeting
Murakami, M., Cabral, H., Matsumoto, Y., Wu, S., Kano, M. R., Yamori, T., Nishiyama, N., & Kataoka, K. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001385 · Cited by 262
Prakash, S., Malhotra, M., Shao, W., Tomaro-Duchesneau, C., & Abbasi, S. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.06.013 · Cited by 256
Koizumi, F., Kitagawa, M., Negishi, T., Onda, T., Matsumoto, S.-I., Hamaguchi, T., & Matsumura, Y. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1605 · Cited by 256
Self-citationPEGylated polymers for medicine: from conjugation to self-assembled systems
Joralemon, M. J., McRae, S., & Emrick, T. (2010) · Chemical Communications · doi:10.1039/b920570p · Cited by 251
Intracellular drug release nanosystems
Meng, F., Cheng, R., Deng, C., & Zhong, Z. (2012) · Materials Today · doi:10.1016/s1369-7021(12)70195-5 · Cited by 250
Pharmapolymers in the 21st century: Synthetic polymers in drug delivery applications
Englert, C., Brendel, J. C., Majdanski, T. C., Yildirim, T., Schubert, S., Gottschaldt, M., Windhab, N., & Schubert, U. S. (2018) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2018.07.005 · Cited by 247
Chen, W., Meng, F., Li, F., Ji, S.-J., & Zhong, Z. (2009) · Biomacromolecules · doi:10.1021/bm900074d · Cited by 240
Improving Penetration in Tumors With Nanoassemblies of Phospholipids and Doxorubicin
Tang, N., Du, G., Wang, N., Liu, C., Hang, H., & Liang, W. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm027 · Cited by 239
Sahu, A., Bora, U., Kasoju, N., & Goswami, P. (2008) · Acta Biomaterialia · doi:10.1016/j.actbio.2008.04.021 · Cited by 239
Nanomaterial standards for efficacy and toxicity assessment
Adiseshaiah, P. P., Hall, J. B., & McNeil, S. E. (2010) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.66 · Cited by 238
Polymeric Micelles: Recent Advancements in the Delivery of Anticancer Drugs
Gothwal, A., Khan, I., & Gupta, U. (2016) · Pharmaceutical Research · doi:10.1007/s11095-015-1784-1 · Cited by 233
“Matsumura et al. (2004) reported phase I clinical trial and pharmacokinetic evaluation of NK 911.”
BackgroundAdvances of Cancer Therapy by Nanotechnology
Wang, X., Wang, Y., Chen, Z. G., & Shin, D. M. (2009) · Cancer Research and Treatment · doi:10.4143/crt.2009.41.1.1 · Cited by 230
Role of Nanotechnology in Pharmaceutical Product Development
Devalapally, H., Chakilam, A., & Amiji, M. M. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20875 · Cited by 230
Enabling individualized therapy through nanotechnology
Sakamoto, J. H., van de Ven, A. L., Godin, B., Blanco, E., Serda, R. E., Grattoni, A., Ziemys, A., Bouamrani, A., Hu, T., Ranganathan, S. I., et al. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2009.12.011 · Cited by 229
Novel Nanomaterials for Clinical Neuroscience
Gilmore, J. L., Yi, X., Quan, L., & Kabanov, A. V. (2008) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-007-9099-6 · Cited by 224
Yokoyama, M. (2010) · Expert Opinion on Drug Delivery · doi:10.1517/17425240903436479 · Cited by 224
“Then, in the 2000s, several significant related clinical trials [14-23] got underway, while more and more R&D projects were conducted.”
BackgroundHussain, Z., Khan, S., Imran, M., Sohail, M., Shah, S. W. A., & de Matas, M. (2019) · Drug Delivery and Translational Research · doi:10.1007/s13346-019-00631-4 · Cited by 220
“PEGylated polymer micelles (NK911) DOX Accumulation of drug in solid tumor Phase I clinical trials [95]”
Background
Metadata
- Authors
- Matsumura, Y., Hamaguchi, T., Ura, T., Muro, K., Yamada, Y., Shimada, Y., Shirao, K., Okusaka, T., Ueno, H., Ikeda, M., & Watanabe, N.
- Affiliations
- National Cancer Center Hospital East (JP)
- National Cancer Center Hospital (JP)
- Nippon Kayaku (Japan) (JP)
- Corresponding author
- Matsumura, Y
- Venue
- British Journal of Cancer
- Published
- 2004-10-12
- Volume
- 91
- Issue
- 10
- Pages
- 1775-1781
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- PMC
- PMC2410050
- OpenAlex
- W2056347214
- Cited by
- 623
- References
- 17
- Citations by year
- 2026: 10 · 2025: 11 · 2024: 20 · 2023: 18 · 2022: 28 · 2021: 35 · 2020: 28 · 2019: 23 · 2018: 25 · 2017: 37 · 2016: 42 · 2015: 38 · 2014: 53 · 2013: 28 · 2012: 54
- FWCI
- 8.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- www.springer.com/tdm (unspecified)
- Locations
- British Journal of Cancer (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Keywords
- doxorubicin, polymeric micelles, supramolecular nanocarriers, maximum tolerated dose, dose-limiting toxicity, neutropenia, pharmacokinetics, solid tumors, metastatic pancreatic cancer, accelerated titration, recommended phase 2 dose, drug delivery
- MeSH terms
- Aged, Antineoplastic Agents, Doxorubicin, Drug Administration Schedule, Female, Humans, Male, Micelles, Middle Aged, Nausea, Neoplasms, Neutropenia, Peptides, Polyethylene Glycols, Vomiting, Maximum Tolerated Dose
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.